USE OF DEXMEDETOMIDINE AND BENZODIAZEPINES IN SEVERE ALCOHOL WITHDRAWAL FOR SEDATION

A randomised controlled trial comparing the total dose of Benzodiazepines with Dexmedetomidine as an adjunct to Benzodiazepine versus standard Benzodiazepine therapy for achieving arousable sedation in patients with Severe alcohol withdrawal. - NIL

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/04/065482

Enrollment

Registered

2024-04-09

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F101- Alcohol abuse

Interventions

Intervention1: Dexmedetomidine,lorazepam,Haloperidol: LORAZEPAM 2MG IV FOR EVERY 2 HOURS •TARGET SEDATION -2 TO 0 WITH RASS SCALE •DEXMEDITOMIDINE INFUSION 0.2-1.4 MCG/ KG/HOUR NOT LONGER THAN 72 HOUR

Eligibility

Inclusion criteria

Inclusion criteria: Patients with severe alcohol withdrawal(F10.231) as defined BY ICD-10 guidelines

Exclusion criteria

Exclusion criteria: Patient under 18 years of age,pregnant women,patients with limited life expectancy due to chronic diseases,patients with pre existing neurological illness,Concomitant Substance abuse

Design outcomes

Primary

Measure	Time frame
To compare differences in Median Benzodiazepine Dose in the First 24-hour among two study groups for maintaining light to moderate sedation with target RASS score of 0 to -2.Timepoint: 24 hours	—

Secondary

Measure	Time frame
Length of ICU stay, sedation quality, The ability to communicate, Haloperidol requirements, CIWA-Ar Score during admission and after 24 hours between two groupsTimepoint: Throughout ICU/ED Admission	—

Countries

India

Contacts

Public ContactAvanish Bhardwaj

Command Hospital Airforce Bangalore

avanishbhardwaj78@gmail.com9914734466

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026